Chemomab Therapeutics Ltd DRC (CMMB NASDAQ) stock market data APIs
$3.0693
0.27(8.8%)
as of October 22, 2025
Try our APIs with
free plan!
Chemomab Therapeutics Ltd DRC Financial Data Overview
Price chart is built with
Anychart
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Prev. Close
3.0693
Open
3.3375
High
3.471
Low
3.0014
52 wk Range
2.39-9.84
Market Cap
17 598 K
Shares Outstanding
5 191 K
EPS
-0.016
Beta
0.524
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Chemomab Therapeutics Ltd DRC data using free add-ons & libraries
Get Chemomab Therapeutics Ltd DRC Fundamental Data
Chemomab Therapeutics Ltd DRC Fundamental data includes:
- Net Revenue:
- EBITDA: -12 613 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Chemomab Therapeutics Ltd DRC News
New
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Sanofi SNY announced that the phase II ElevAATe study, which evaluated its pipeline candidate, efdoralprin alfa, for the treatment of alpha-1 antitrypsin deficiency (AATD) emphysema, met all primary a...
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
Roche RHHBY announced that the FDA has approved a regulatory filing seeking the label expansion of Gazyva/Gazyvaro (obinutuzumab) to treat adult patients with active lupus nephritis (LN) who are recei...
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
Novo Nordisk NVO received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction in adults...
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion Therapeutics ESPR announced that it has nominated ESP-2001, a highly specific allosteric ATP citrate lyase (“ACLY”) inhibitor, as its new preclinical development candidate for the treatme...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
